Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.64 |
| ▸ | HTR2A | P28223 | 6/20 | 0.64 |
| ▸ | HTR1A | P08908 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
| ▸ | FFAR2 | O15552 | 7/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3643005 | 0.99 | HTR6 (0.63) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL13359008 | 0.93 | HTR6 (0.67) | HTR6HTR2AHTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL3647127 | 0.92 | HTR6 (0.66) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL13359012 | 0.89 | HTR6 (0.61) | HTR6HTR2AHTR1ADRD2HTR7 | |
| Hydrochloric Acid SCHEMBL3651056 | 0.88 | HTR6 (0.60) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL13359013 | 0.85 | HTR2A (0.59) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL19327116 | 0.85 | HTR6 (0.68) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL19327110 | 0.85 | HTR6 (0.68) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL19327111 | 0.85 | HTR6 (0.68) | HTR6HTR2AHTR1ADRD2HTR7 | |
| SCHEMBL3646817 | 0.84 | HTR6 (0.58) | HTR6HTR2AHTR1ADRD2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185555-B1 | QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBVIE DEUTSCHLAND (DE) | 2016-03-16 | — | — | EP | claimed |